Predictive biomarkers for oncology are necessary to accurately identify patients who will benefit from anticancer treatment. Recently approved oncology drugs target discrete molecular aberrations or pathways in tumor cells and consequently are active on a subset of patient population, yet clinical studies have shown that not all biomarker-positive patients respond. The advancement of predictive biomarkers needs to detect novel and evolving drug resistance mechanisms, not only to guide the selection of patient subsets for specific treatments, but to identify new therapeutic targets.
Oncology Markets for IDH Inhibitors Report Brochure (Download PDF)
Oncology Markets for IDH Inhibitors Report Order Form (Download PDF)
What You Will Learn
- Who are the developers and suppliers of IDH inhibitors? What are their capabilities and market strategies?
- What is the competitive landscape for late-stage development IDH inhibitors and what indications are they targeting?
- What is the size of the market for IDH inhibitors today, who are the market share leaders, and what will the market be in 2022?
- How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
- What are the significant economic, technology, and regulatory factors affecting the market for biomarker-based oncology therapeutics?
Oncology Markets for IDH Inhibitors – Summary of Contents
Mutated IDH – Mechanisms of Action
IDH Inhibitor Therapeutics
Inhibition of IDH
FDA-Approved IDH Inhibitors
Acute Myeloid Leukemia
Competing Drugs Prescribed for Treating AML
Gemtuzumab ozogamicin (Mylotarg)
Hedgehog pathway inhibitor
Non-small Cell Lung Cancer
Pharmaceutical Insurance Coverage & Managed Care